Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanobiotix - Revenue for the second quarter of 2013

Abstract:
NANOBIOTIX (Euronext : NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2013.

Nanobiotix - Revenue for the second quarter of 2013

Paris, France | Posted on July 13th, 2013

Income statement



in €


Q2 2013*


H1 2013

Revenue

of which :

License

Services

48,569

45,847

2,722

95,050

93,328

2,722

*over the second quarter of 2012, the company recorded no revenue

Activity

As in previous quarters, revenue recorded during the second quarter of 2013 corresponds to the pro rata share of the first payment received by the company within the framework of the licensing contract signed with PharmaEngine, the Taiwan-based biopharmaceutical company, in August 2012, which covers the development and commercialization of NBTXR3 in the Asia-Pacific region. This upfront payment amounts to €810,640, generating a product of €45,847 for the period and totalling €92,328 for the first semester in 2013. The invoicing of services totalled €2,722 for the period. In total, revenue for the second quarter amounts €48,569. Revenue for the first half of 2013 is €95,050 which is fully in line with Company expectations.

Nanobiotix remains focused on the clinical development of its lead products where commercialization is planned for 2017. Recent positive news flow, especially in June, indicates the successful implementation of Nanobiotix's strategy in line with the Company's development plan. In June, Nanobiotix published encouraging preliminary results for lead product NBTXR3 with clinical proof of concept, safety and security of the intratumoral injection in patients with soft tissue sarcoma. In parallel, Nanobiotix has received approval from ANSM to start a new clinical trial for NBTXR3 in head and neck cancer patients, a major concern in terms of public health in European countries and across Asia. Nanobiotix has also initiated the preclinical development of NBTX-IV, the second product from the NanoXray pipeline, through collaboration with the US National Cancer Institute (NCI).

Financial calendar

Results for the first half of 2013, on August 30, 2013

####

About Nanobiotix
Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product, NBTXR3 based on NanoXray, is currently under clinical development for soft tissue sarcoma. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The Company is based in Paris, France.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

For more information, please click here

Contacts:
Nanobiotix

Laurent Levy
CEO
+33 (0)1 40 26 07 55


NewCap.
Financial communication
and investors relations
Louis-Victor Delouvrier
Emmanuel Huynh
+33 (0)1 44 71 98 53


Yucatan
Media relations (France)
Annie-Florence Loyer
Nadège Le Lezec
+33 (0)1 53 63 27 27
+33 (0)6 88 20 35 59


College Hill
Media relations (Outside France)
Melanie Toyne Sewell
Claire Dickinson
Donia Al Saffar
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

GLOBALFOUNDRIES Announces Availability of 45nm RF SOI to Advance 5G Mobile Communications: Optimized RF features deliver high-performance solutions for mmWave beam forming applications in 5G smartphones and base stations February 22nd, 2017

EmTech Asia breaks new barriers with potential applications of space exploration with NASA and MIT February 22nd, 2017

JPK selects compact tensile stage from Deben for their NanoWizard® AFM platform to broaden capabilities for materials characterisation February 22nd, 2017

Molecular phenomenon discovered by advanced NMR facility: Cutting edge technology has shown a molecule self-assembling into different forms when passing between solution state to solid state, and back again - a curious phenomenon in science - says research by the University of Wa February 22nd, 2017

Govt.-Legislation/Regulation/Funding/Policy

Molecular phenomenon discovered by advanced NMR facility: Cutting edge technology has shown a molecule self-assembling into different forms when passing between solution state to solid state, and back again - a curious phenomenon in science - says research by the University of Wa February 22nd, 2017

'Lossless' metamaterial could boost efficiency of lasers and other light-based devices February 20th, 2017

Engineers shrink microscope to dime-sized device February 17th, 2017

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanomedicine

Nominations Invited for $250,000 Kabiller Prize in Nanoscience: Major international prize recognizes a visionary nanotechnology researcher February 20th, 2017

Good vibrations help reveal molecular details: Rice University scientists combine disciplines to pinpoint small structures in unlabeled molecules February 15th, 2017

In-cell molecular sieve from protein crystal February 14th, 2017

Cedars-Sinai, UCLA Scientists Use New ‘Blood Biopsies’ With Experimental Device to Speed Cancer Diagnosis and Predict Disease Spread: Leading-Edge Research Is Part of National Cancer Moonshot Initiative February 13th, 2017

Announcements

GLOBALFOUNDRIES Announces Availability of 45nm RF SOI to Advance 5G Mobile Communications: Optimized RF features deliver high-performance solutions for mmWave beam forming applications in 5G smartphones and base stations February 22nd, 2017

EmTech Asia breaks new barriers with potential applications of space exploration with NASA and MIT February 22nd, 2017

JPK selects compact tensile stage from Deben for their NanoWizard® AFM platform to broaden capabilities for materials characterisation February 22nd, 2017

Molecular phenomenon discovered by advanced NMR facility: Cutting edge technology has shown a molecule self-assembling into different forms when passing between solution state to solid state, and back again - a curious phenomenon in science - says research by the University of Wa February 22nd, 2017

Financial Reports

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results January 31st, 2017

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 7, 2017 January 19th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Harris & Harris Group Issues Business Update and Reports Financial Statements as of September 30, 2016 November 9th, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project